ABSTRACT
Seronegative spondylorthropathies are a group of disorders with similar etiopathogenesis which are seen in genetically proned individuals with chronic inflamatory symptoms. Prototype of this group of disorders is ankylosing spondylitis which involve the axial skeletal system. Clinicaly it does not only effect skeletal sytem but also enthesis areas, joints , eyes, intestines and skin may get involved. Microbial dysbiosis takes an important place in etiopathogenesis. Dysbiosis cause mucosal barier disruption therefore induces releasing of inflamatory cytokines. Th3 type immunity which plays a major role in mucosal integrity , is major factor in inflamatory process and its numbers increase in these patients. Stability of mucosal barier function is also effected by IL-17, IL-22 along with Th3 type of immunity. As a result , activated immune system with different inducers cause chronic inflamatory reaction with inflamatory cytokines with the help of IL-17 and IL-23 thereby lead to spondylitis.
References
1Hüffmeier U, Lascorz J, Böhm B, et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis andpsoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009;129:355-8.
2Wellcome Trust Case Control Consortium, Burton PR, Clayton DG, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
3Farh KKH, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015;518:337-43.
4Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T cell functional responses. Proc Natl Acad Sci USA 2011;108:9560-5.
5Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune- mediated diseases byimpairing IL-23-induced Th17 effector response in humans. PLoS ONE 2011;6:e17160.
6Winchester R, Giles J, Jadon D, Haroon M, McHugh N, FitzGerald O. Implications of the diversity of class I HLA associations in psoriatic arthritis. Clin Immunol 2016;172:29-33.
7Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R. CD8+ T cell autoreactivity to an HLA-B27- restricted self- epitope correlates with ankylosing spondylitis. J Clin Invest 2000;106:47-53.
8DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA- B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009;60:2633-43.
9Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G. From HLA- B27 to spondyloarthritis: a journey through the ER. Immunol Rev 2010;233:181-202.
10Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA- B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011;186:2672-80.
11Saric T, Chang SC, Hattori A, et al. An IFN-γ-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I- presented peptides. Nat Immunol 2002;3:1169-76.
12International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 2013;45:730-8.
13Evans DM, Spencer CCA, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011;43:761-7.
14Woolf E, Xiao C, Fainaru O, et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 2003;100:7731-6.
15Shan Q, Zeng Z, Xing S, et al. The transcription factor Runx3 guards cytotoxic CD8+ effector T cells against deviation towards follicular helper T cell lineage. Nat Immunol 2017;18:931-9.
16Australo-Anglo-American Spondyloarthritis Consortium, Reveille JD, Sims AM, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010;42:123-7.
17Saveanu L, Carroll O, Lindo V, et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 2005;6:689-97.
18Kochan G, Krojer T, Harvey D, et al. Crystal structures of the endoplasmic reticulum aminopeptidase 1 (ERAP1) reveal the molecular basis for N terminal peptide trimming. Proc Natl Acad Sci USA 2011;108:7745-50.
19Garcia-Medel N, Sanz-Bravo A, Van Nguyen D, et al. Functional interaction of the ankylosing spondylitis-associated endoplasmic reticulum aminopeptidase 1 polymorphism and HLA B27 in vivo. Mol Cell Proteomics 2012;11:1416-29.
20van Duivenvoorde LM, Dorris ML, Satumtira N, et al. Relationship between inflammation, bone destruction, and osteoproliferation in the HLA- B27/human β2 -microglobulin- transgenic rat model of spondylarthritis. Arthritis Rheum 2012;64:3210-9.
21Aschermann S, Englbrecht M, Bergua A, et al. Presence of HLA- B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway. Joint Bone Spine 2016;83:43-6.
22Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60:3257-62.
23Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003;426:454-60.
24Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol 2015;135:626-35.
25Gracey E, Qaiyum Z, Almaghlouth I, et al. IL-7 primes IL-17 in mucosal associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis 2016;75:2124-32.
26Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol 2018;53:379-89.
27Konig J, Wells J, Cani PD, et al. Human intestinal barrier function in health and disease. Clin Transl Gastroenterol 2016;7:e196.
28Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol 2018;36:755-81.
29Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009;206:1465-72.
30Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 2015;43:727-38.
31Cuthbert RJ, Fragkakis EM, Dunsmuir R, et al. Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol 2017;69:1816-22.
32Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4 lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
33Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13:3-10.
34Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol 2008;1:364-71.
35Sefik E, Geva-Zatorsky N, Oh S, et al. Mucosal immunology. Individual intestinal symbionts induce a distinct population of RORγ+ regulatory T cells. Science 2015;349:993-7.
36Ohnmacht C, Park JH, Cording S, et al. Mucosal immunology. The microbiota regulates type 2 immunity through RORγ+ T cells. Science 2015;349:989-93.
37Gagliani N, Vesely MCA, Iseppon A, et al. TH17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 2015;523:221-5.
38Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondylarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011;13:R95.
39Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014;14:585-600.
40Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
41Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-8.
42Wu C, Yosef N, Thalhamer T, et al. Induction of pathogenic TH17 cells by inducible salt- sensing kinase SGK1. Nature 2013;496:513-7.
43Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)1 cells in the absence of TGF- β signalling. Nature 2010;467:967-71.
44Song X, He X, Li X, Qian Y. The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol 2016;13:418-31.
45Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice. Eur J Immunol 2015;45:2171-82.
46Keijsers RR, Joosten I, van Erp PE, Koenen HJ, van de Kerkhof PC. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol 2014;23:799-803.
47Razawy W, van Driel M, Lubberts E. The role of IL-23 receptor signaling in inflammation- mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol 2018;48:220-9.
48Wei L, Laurence A, Elias KM, O’Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007;282:34605-10.
49Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012;13:991-9.
50Paulissen SM, van Hamburg JP, Dankers W, Lubberts E. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine 2015;74:43-53.
51Hirota K, Yoshitomi H, Hashimoto M, et al. Preferential recruitment of CCR6- expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007;204:2803-12.
52Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708.
53Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008;9:641-9.
54Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010;467:967-71.
55Kao CY, Huang F, Chen Y, et al. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK- independent but MEK/NF-κB-dependent signaling pathway. J Immunol 2005;175:6676-85.
56Shahrara S, Pickens SR, Mandelin AM, et al. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 2010;184:4479-87.
57Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995;155:5483-6.
58Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007;179:4135-41.
59Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000;12:1092-9.
60Koenders MI, Kolls JK, Oppers-Walgreen B, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall induced arthritis. Arthritis Rheum 2005;52:3239-47.
61Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
62Pickens SR, Volin MV, Mandelin AM, Kolls JK, Pope RM, Shahrara S. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010;184:3233-41.
63Gullick NJ, Evans HG, Church LD, et al. Linking power Doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLOS One 2010;5:e12516.
64Fiorillo MT, Maragno M, Butler R, Dupuis, ML, Sorrentino R. CD8+ T cell autoreactivity to an HLAB27- restricted self- epitope correlates with ankylosing spondylitis. J Clin Invest 2000;106:47-53.
65DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA- B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009;60:2633-43.
66Kawashiri SY, Kawakami A, Iwamoto N, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast- like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease- modifying antirheumatic drugs. J Rheumatol 2009;36:2397-402.
67Zhang Y, Ren G, Guo M, et al. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen- induced arthritis mouse model. Int Immunopharmacol 2013;15:199-205.
68Teunissen MBM, Bos JD, Koomen CW, de Waal Malefyt R, Wierenga EA. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9.
69Sathaliyawala T, Kubota M, Yudanin N, et al. Distribution and compartmentalization of human circulating and tissue- resident memory T cell subsets. Immunity 2013;38:187-97.
70Iijima N, Iwasaki A. Tissue instruction for migration and retention of TRM cells. Trends Immunol 2015;36:556-64.
71Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-7.
72Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009;24:1572-85.
73Kocijan R, Englbrecht M, Haschka J, et al. Quantitative and qualitative changes of bone in psoriasis and psoriatic arthritis patients. J Bone Miner Res 2015;30:1775-83.
74Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum 1992;35:1062-7.
75Donnelly S, Doyle DV, Denton A, Rolfe I, McCloskey EV, Spector TD. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994;53:117-21.
76Neerinckx B, Lories R. Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis. Curr Opin Rheumatol 2017;29:287-92.
77Simon D, Faustini F, Kleyer A, et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis 2016;75:660-6.
78Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
79Schett G. Review: immune cells and mediators of inflammatory arthritis. Autoimmunity 2008;41:224-9.
80Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha- induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a “fine- tuning cytokine” in inflammation processes. Arthritis Rheum 2001;44:2176-84.
81Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL- β and TNF- α, by human macrophages. J Immunol 1998;160:3513-21.
82Yago T, Nanke Y, Kawamoto M, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti- IL-23 antibody attenuates collagen- induced arthritis in rats. Arthritis Res Ther 2007;9:R96.
83Osta B, Lavocat F, Eljaafari A, Miossec P. Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front Immunol 2014;5:425.
84Li X, Kim KW, Cho ML, et al. IL-23 induces receptor activator of NF- κB ligand expression in fibroblast- like synoviocytes via STAT3 and NF- κB signal pathways. Immunol Lett 2010;127:100-7.
85Quinn JM, Sims NA, Saleh H, et al. IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol 2008;181:5720-9.
